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ABSTRACT  
Introduction 
The aim of this study was to compare adverse events and surgical outcomes of 
hysterectomy with or without use of a gelatin-hemostatic matrix (SURGIFLO®). 
Materials and Methods 
Prospective case-control study (Canadian Task Force classification II2) of total 
hysterectomy (Piver Type 1) provided by surgeons in Australia between Nov 2005 
and May 2015. Data were collected via SurgicalPerformance, a web-based data 
project which aims to provide confidential feedback to surgeons about their surgical 
outcomes. Of 2,440 records of women who received a hysterectomy, 1,351 were 
eligible for these analyses, 107 received SURGIFLO® hemostatic matrix to prevent 
postoperative blood loss and 1,244 did not receive SURGIFLO®. 
Results 
Patients with or without SURGIFLO® differed in age, Charlson co-morbidity index, 
and American Society of Anesthesiologists physical status classification system score 
(ASA), and also differed in clinical outcomes. After matching for patient’s age and 
ASA at surgery, patients with and without SURGIFLO® had comparable baseline 
characteristics. Matched patients with and without SURGIFLO® had comparable 
clinical outcomes including risk of developing vault hematoma, return to the 
operating room, transfusion of red cells, surgical site infection (pelvis), readmission 
within 30 days and unplanned ICU admission. 
Conclusions 
In a sample matched by age and ASA, SURGIFLO® neither prevents nor causes 
additional adverse events in women undergoing hysterectomy. Surgeons used 
SURGIFLO® more commonly among women who were older, had more 
comorbidities and a higher ASA score. This indicates that it may be most useful in 
complicated surgery or cases.  
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Keywords: 
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Abbreviations: 
ASA: American Society of Anesthesiologists 
Key Message: (limit 40 words) 
 We present outcomes on the use of SURGIFLO®  in a series of 214 women 
(of whom 107 received SURGIFLO®) who required a hysterectomy.   
 SURGIFLO® may be useful in complicated surgery and no additional adverse 
events were found.   
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INTRODUCTION 
Hysterectomy is the most common major gynecological procedure performed. More 
than 430,000 hysterectomies are performed in the US every year (1) and in Australia 
about 30,000 women require a hysterectomy every year for various gynecological 
conditions (2, 3). Most hysterectomies are performed for benign, non-cancerous 
conditions such as fibroids, menorrhagia or pelvic pain (1).  
Not uncommonly extensive dissection in the pelvis will leave raw areas that are 
potential sources of bleeding post operatively.  Patients who require a hysterectomy 
for adenomyosis or endometriosis, patients with dense adhesions and patients who 
had surgery previously are at risk of increased intraoperative blood loss (4). Risk 
factors for post-hysterectomy abscess formation include untreated pelvic 
inflammatory disease, endometriosis, previous laparotomy and post-operative 
hematoma. Patients with higher intraoperative blood loss have a higher risk of long 
hospital stay and are more likely to require transfusion of red cells postoperatively (5). 
The incidence of post-hysterectomy vaginal vault hematoma is between 19.4% and 
73% (6-10). A hematoma may get infected, require intravenous antibiotics, 
hospitalization and sometimes even surgical evacuation or resuturing for vaginal vault 
dehiscence (11, 12). 
SURGIFLO® hemostatic matrix is approved for routine use for many years 
worldwide. It is a sterile, absorbable porcine gelatin intended to aid with hemostasis 
when applied to a bleeding surface (13). It allows intimate tissue contact to an 
irregular wound bed, such as pelvic surfaces after surgery. Upon contact with blood, 
acceleration of clot formation is reinforced with the incorporation of the 
gelatin/thrombin within the fibrin clot (13). It can be applied through open and 
laparoscopic pelvic surgery.  
While SURGIFLO® is widely used globally, its efficacy has never been formally 
evaluated in the setting of a randomized controlled clinical trial but was approved 
based on similarity with a formulation that was (14). The available literature on 
SURGIFLO® is sparse. A PubMed literature search until January 2015 revealed nine 
publications (15-23), four of which are on animal models.  Of the five publications 
describing clinical studies, all but one describes the use in clean surgery (15-19).  
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Clean-contaminated surgery refers to surgery with expected contamination when the 
procedure opens a colonized viscus or cavity under surgical circumstances. Any total 
hysterectomy requiring the opening of the vagina is classified as “clean-contaminated” 
because of the possibility of ascension of germs through the vagina.  Generally, 
surgical site infection rates are higher in clean-contaminated surgery (22%) than in 
clean surgery (3%) (24) (25). In the setting of clean-contaminated surgery, any 
prosthesis or foreign material that is introduced or left behind in the body (for 
example, mesh, adhesion barriers, hemostatic agents) may increase the risk of surgical 
site infections even more (26). Unfortunately no evidence is available on the safety 
and efficacy of SURGIFLO® in the context of gynecological surgery and in particular 
in hysterectomy. 
The present study is the first formal evaluation of SURGIFLO® in the context of 
hysterectomy. We present outcomes on safety and efficacy of SURGIFLO® in order 
to inform the design of a definitive trial on its efficacy.  
 
 
MATERIAL AND METHODS 
The study is a non-randomized prospective case-control study. The study uses data 
collected for clinical audit and met the requirements in Section 5.1.22 a & b of the 
Australian National Statement on Ethical Conduct in Human Research 2007, which 
means that the study was exempted from formal human research and ethics committee 
review by the Royal Brisbane and Women’s Hospital Human Research and Ethics 
Committee because data being accessed are non-identifiable. Informed consent was 
not sought from the participants, as SURGIFLO® is a Therapeutic Goods Association 
(TGA) approved intervention and routinely used in Australia. 
 
Women were eligible if they were female, 18 years of age or older, who required a 
total hysterectomy (laparoscopic or abdominal) for benign conditions as well as for 
uterine cancer (Piver Class 1), and whose intraoperative blood loss was 100 ml or 
greater. Women were excluded if they were to have a subtotal hysterectomy, a radical 
hysterectomy as part of cervical or ovarian cancer surgery, or if postoperative follow 
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up was not available. For the aim of this study, women were also excluded if there 
was a need for concurrent use of a haemostatic agent other than SURGIFLO®. 
 
Data were collected using SurgicalPerformance PTY LTD, a web-based data project 
designed by surgeons which aims to provide confidential feedback about treatment 
outcomes to O&G surgeons for clinical audit.  Besides being an audit tool, 
SurgicalPerformance can also be used to prospectively evaluate the safety of surgical 
devices. SurgicalPerformance independent of any professional standards body 
(governmental or non-government), and data are not shared with third parties, 
confidential and protected under the Commonwealth Qualified Privilege Scheme. 
Only non-identifiable data are used for clinical research. The vast majority of data 
currently entered in Surgical Performance comes from Australian centres. 
At the time of data entry, surgeons will be encouraged not to reveal identifiable 
patient information. Patient identity is anonymous, and secured by a code that only 
the surgeon has access to, enabling postoperative follow up at 6 weeks from surgery.  
Access to SurgicalPerformance is through secure login and password, and RapidSSL 
(Secure Socket Layer) Certificate guarantees encryption of all data transfers, 
protecting all data from interference. An audit Log records user, date and time, IP 
address from where changes were made; deleting of records is not possible to protect 
users from accusations of falsifying records. SurgicalPerformance is web-based, and 
its servers are located in the cloud. SurgicalPerformance can be used for free, at no 
cost.  
Data has been collected form a plurality of general gynaecologists and gynaecological 
oncologists worldwide who comprise existing and new users of SurgicalPerformance. 
All users of SurgicalPerformance agree that data may be used for research.  
Data collected at baseline include surgeon’s hospital/institution, patient’s identity (ID) 
number (non-identifiable), ethnicity, date of birth and date of surgery (age at surgery), 
pre-existing medical co-morbidities (Charlson score), body weight and height and 
ASA score.  
Data collected at surgery include the main indication for hysterectomy, primary 
surgical approach (laparoscopic, open, robotic). Typically the use of SURGIFLO® 
was recorded at the time of surgery.  
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Data on intraoperative effectiveness of SURGIFLO® was not collected.  
Treatment 
All women received a total hysterectomy (Piver Type 1) for various indications. The 
hysterectomy was completed minimally invasive or open through an abdominal 
incision. The vaginal vault was sutured and careful hemostasis was attempted. 
Patients with uterine cancer may have had a retroperitoneal node dissection, based on 
the surgeon’s preference or local guidelines.  
Patients did or did not receive SURGIFLO® hemostatic matrix and the decision to 
apply SURGIFLO® was based on surgeon’s ad hoc preference, without 
randomization. SURGIFLO® has been administered to treat bleeding or to prevent it. 
While the application of SURGIFLO® hemostatic matrix was not standardized, it is 
typically prepared immediately before use and applied to the vaginal vault and/or to 
the lateral pelvic walls with a single-barrel syringe. Typically one standard dose of 
SURGIFLO® is applied to the vaginal vault and adjacent tissues. If a pelvic lymph 
node dissection is performed another one to two doses would be applied to one or 
both obturator fossae (lateral pelvic walls).  
All women were followed for four to six weeks after surgery and any adverse effects 
associated with surgery within the follow up period were recorded. Women whose 
postoperative follow-up was not completed were not eligible for analysis. Outcomes 
were classified as 1. Vaginal vault hematoma detected clinically and confirmed 
radiologically or surgically; 2. Return to the operating room to manage postoperative 
bleeding; 3. Requirement of postoperative transfusion of red cells; 4. Pelvic 
infection/deep surgical site infection detected clinically and/or radiologically. 
Data Management 
All data, including the adverse events outcomes were entered directly into 
SurgicalPerformance by the gynecologists or their representatives. No hard copies 
were completed. A comprehensive validation check program was used to validate 
data at data entry level. Only data sets that had all mandatory data fields completed 
were used for statistical analysis and reporting. Cross checks of data entered and 
source data were not conducted due to the nature of the population-based database. 
Only de-identified clinical information was used for statistical analysis and reporting. 
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Records were extracted from the SurgicalPerformance database in July 2015 and 
submitted for independent statistical analysis.  
Statistical Analysis 
IBM SPSS Statistics, version 21 was used for all analyses. To summarize patient 
characteristics, means and standard deviations or frequencies and proportions were 
calculated. We then compared the incidence of adverse events associated with the 
surgical procedure between patients who did and who did not receive intraoperative 
SURGIFLO® using independent Students t-tests for continuous and Chi-Square tests 
for categorical variables.  
Given the stark differences in American Society of Anesthesiologists physical status 
classification system score (ASA) and age between patients who did or did not 
receive SURGIFLO® (Table 1), and in order to reduce the unequal distribution of 
confounding factors we individually matched one patient without SURGIFLO® to 
each patient who had received SURGIFLO® by age and ASA score.  
From the 1244 patients without SURGIFLO®, an equal proportion of patients with 
ASA scores 1-3 were selected to match the age and ASA distribution among patients 
with SURGIFLO®, (35%, 43% and 22% with ASA 1,2 and 3, respectively) (27). This 
resulted in Charlson comorbidity index score, estimated blood loss and Body Mass 
Index becoming similarly distributed between the two matched groups (Table 1). 
We then recalculated the presence/absence of post-operative adverse events within the 
214 patients with or without SURGIFLO®, and used Conditional Logistic Regression 
tests to determine differences in the proportion with adverse events. 
 
Results 
A total of 2,440 records of women who had received a hysterectomy were available as 
of July 1, 2015. Of those, 889 women were excluded because they did not fulfill one 
or more of the inclusion criteria. Of the remaining 1,351, 107 patients received 
SURGIFLO® and 1,244 did not receive SURGIFLO®.  
Patient characteristics are detailed in table 1. In brief, patients in the SURGIFLO® 
group were significantly older, had a higher Charlson co-morbidity index and were 
more likely to be given an ASA score of 2 (mild systemic disease) or 3 (severe 
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systemic disease). Patients in the SURGIFLO® group were more likely to have a 
laparoscopic hysterectomy than an open, abdominal hysterectomy. 
Upon comparing the frequencies, patients who received SURGIFLO® more often 
developed a surgical site infection in the pelvis (6.5% vs. 1.2%) or had to be 
readmitted to hospital more often (7.5% vs. 2.5%) (Table 2).  
After matching for patient’s age and ASA at surgery, patients with and without 
SURGIFLO® had comparable baseline characteristics (Table 1).  
Comparing the matched cohorts using conditional logistic regression analysis, 
patients with and without SURGIFLO® had comparable clinical outcomes in regards 
to the risk of developing vault hematoma, return to the operating room, transfusion of 
red cells, surgical site infection (pelvis), and readmission within 30 days. No 
unplanned ICU admissions were recorded in the SURGIFLO® group (Table 2). 
 
Discussion 
These data show that SURGIFLO® neither prevented nor increased surgical 
complications related to bleeding in patients who had a hysterectomy. After careful 
matching for ASA and patient’s age at the time of surgery, surgical outcomes in 
patients who had and did not have SURGIFLO® were similar in this series.  
While SURGIFLO® is widely and routinely used, data on surgical outcomes in 
humans are sparse. Tackett and colleagues reported surgical outcomes following 
SURGIFLO® vs Floseal (a hemostatic matrix plus Thrombin) use in patients 
requiring cardiac surgery using administrative data (18). Comparing Floseal 
(n=4,480) and SURGIFLO® (n= 326), SURGIFLO® use was associated with a 
higher risk of adverse outcomes including major and minor complications when 
compared to Floseal. Given the disparity in sample sizes between the groups and 
potential confounding, interpretation of the data should be approached with caution.  
Buiret and colleagues from France reported two case reports of successful 
haemostasis with SURGIFLO® in patients with epistaxis (19). Woodworth et al 
reported a 96.7% success rate in haemostasis in 30 patients undergoing endoscopic 
sinus surgery for chronic sinusitis (13). Both groups stated that no surgical 
complications were observed.  
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Bannister and Ah-See reported 17 cases of hemostasis using SURGIFLO® in patients 
requiring excisions of the submandibular gland (17). No complications were reported 
within the duration of hospital stay but no information was provided on outcomes 
beyond the discharge from hospital.  
Gazzeri reported the use of SURGIFLO® and Floseal in 231 patients requiring 
haemostasis for brain surgical procedures (15). SURGIFLO® was used to minimize 
the damage from conventional hemostasis on brain tissue. The report does not contain 
a breakdown of data on patients’ surgical outcomes between SURGIFLO® and 
Floseal.  
The literature available on other hemostatic agents generally does not suggest 
increased morbidity subsequent to the use of Floseal, Surgicel or Fibrillar. A 2014 
meta-analysis evaluating the efficacy of Floseal in total knee arthroplasty patients 
found no differences in postoperative drainage volume, incidence of wound infection, 
deep vein thrombosis and pulmonary embolism between Floseal and controls(28). 
Similarly, a study comparing post-thyroidectomy bleeding and infection rates of 98 
patients who received Surgicel versus 92 patients who did not receive Surgicel found 
similar outcomes (29).  
By contrast, a recent paper suggested an increased risk of postoperative abscess in 
major gynecologic oncology surgery with fibrillar(30). Fibrillar was used in 21% of 
patients and infections occurred in 9.7% of the patients overall. Infections were 8 to 
12 times more likely in patients who received an absorbable hemostatic agent but the 
number of cases was low, and no definitive conclusions could be reached. 
In our study the estimated blood loss of all patients was approximately 250 ml, which 
is higher than expected in an uncomplicated hysterectomy. However, only patients 
with an estimated blood loss of 100 ml or greater were considered eligible. The 
estimated blood loss of patients who did and who did not receive SURGIFLO® was 
similar, which infers that SURGIFLO® was mainly used for prevention of 
postoperative bleeding. The intraoperative effectiveness of SURGIFLO® as a 
hemostatic agent was not evaluated. The incidence of vault hematoma and the 
requirements of red cell transfusion were identical in patients who received and who 
did not receive SURGIFLO®.  
Prior to matching, patients in the SURGIFLO® more often developed a surgical site 
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infection in the pelvis (6.5% vs. 1.2%) or had to be readmitted to hospital more often 
(7.5% vs. 2.5%). However, at the time of statistical analysis we realized that both 
samples were vastly different in regards to baseline patients’ characteristics (Table 1) 
and therefore we matched the cases by controls of similar characteristics. Matching 
for ASA and age resulted comparable clinical outcomes in patients who received and 
who did not receive SURGIFLO® (Table 2). Hence, we conclude that co-morbidities 
rather than the intervention may be the cause for the differences we observed initially.  
To our best knowledge, the present study represents the only evaluation of 
SURGIFLO® in gynecological surgery to date. We were particularly interested in the 
outcomes of SURGIFLO® in the context of hysterectomy because it is the most 
common gynecological major procedure. In addition, hysterectomy represents clean-
contaminated surgery with its inherent risk of vault hematoma and infection. A 
foreign body could possibly increase the ascension of germs and cause infections.  
Admittedly, the present study has limitations that need to be acknowledged. First, the 
selection of subject group assignment by the clinicians submitting data to 
SurgicalPerformance need to be considered a potential source of bias that may not 
have been corrected by the matching methodology. Secondly, the study design 
involves the analysis of self-reported data and no checks and crosschecks are possible 
as would be the case in the context of a clinical trial. SurgicalPerformance represents 
a community of users and needs to operate in full confidentiality to protect sensitive 
data and achieve its objectives. In turn, this allows the analysis of real-world data that 
are not guarded by the regulations of clinical trials. Given that the data were collected 
outside a randomized controlled clinical trial the influence of confounders, such as 
patients’ age, ASA score and medical co-morbidities predict surgical adverse 
outcomes are difficult to isolate.  
Thirdly, the incidence of surgical adverse events is low and while the present study 
failed to detect a significant difference in various outcomes, failing to detect a 
difference is also possible due to the low effective sample size. However, the results 
of this study can be used to plan future research on SURGIFLO®. The data on the 
incidence of vault hematoma with and without SURGIFLO® and the data on pelvic 
infection are unique and can be used to determine the number of patients required for 
a future prospective, randomized trial. 
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The present study provides first data on the outcomes of SURGIFLO® use in the 
context of hysterectomy. The results suggest that clinical outcomes of patients with 
and without SURGIFLO® are similar.  
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Table 1: Distribution of frequencies of SURGIFLO® use (Patient characteristics) 
 
 Overall 
N=1351 (%) 
No 
SURGIFLO®  
N=1244 (%) 
Unmatched 
sample 
SURGIFLO®  
N= 107(%) 
Test value*; p-
value 
Matched sample  
No SURGIFLO® 
N=107 (%) 
Age at surgery 
(Years)  
50.9 (10.5) 49.9 (9.9) 56.4 (12.6) 18.6; <0.01 53.9 (13.1) 
Charlson score  0.96 (1.32) 0.91 (1.27) 1.96 (1.68) 23.2; <0.01 1.57 (1.64) 
Estimated blood loss (ml) 247.2 (219.7) 245.1 (219.1) 261.4 (227.6) 0.27;0.46 252.6 (167.2) 
Body Mass Index (kg/m2)  29.9 (8.9) 29.4 (9.1) 30.4 (7.5) 0.09;0.36 31.8 (6.9) 
ASA score     67.9; <0.001  
Normal healthy patient 803 (59.4) 766 (61.6) 37 (34.6)  37 (34.6) 
Patient with mild systemic 
disease 
468 (34.6) 422 (33.9) 46 (43.0)  47 (43.9) 
Patient with severe systemic 
disease or Severe systemic 
disease, constantly life 
threatening 
80 (5.9) 57 (4.5) 24 (22.4)  23 (21.5) 
Indication for surgery    39.6; <0.001  
Leiomyoma 354 (26.1) 342 (27.4) 12 (11.2)  21 (19.6) 
Pelvic pain 130 (9.6) 119 (9.6) 11 (10.3)  11 (10.3) 
Abnormal uterine bleeding 483 (35.7) 446 (35.8) 37 (34.3)  27 (25.2) 
Premalignant/Prophylactic 124 (9.2) 120 (9.6) 4 (3.7)  13 (12.1) 
Other 263 (19.4) 219 (17.6) 43 (40.2)  35 (32.7) 
Previous laparotomy (yes) 497 (37.0) 43 (40.2) 436 (36.7) 0.51; 0.47 43 (40.6) 
Surgical approach    56.6; <0.001  
Abdominal 364 (26.9) 351 (28.2) 13 (12.1)  24 (22.4) 
Laparoscopic 582 (43.1) 499 (40.1) 83 (77.6)  45 (42.1) 
Other 405 (30.0) 394 (31.7) 11 (10.3)  38 (35.5) 
*Student’s T test for continuous variables; Chi-Square test for categorical variables 
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Table 2: Chi-Square tests (No SURGIFLO® vs. SURGIFLO®) (blue brackets) and Conditional Logistic Regression (No SURGIFLO® - 
matched sample vs. SURGIFLO®) (red brackets) to determine the risk of adverse events. 
 
 
 
 
Outcomes Overall 
N=1351 
(%) 
No 
SURGIFLO® 
N=1244 (%) 
SURGIFLO® 
N= 107 (%) 
2 value; p-
value 
 No 
SURGIFLO®  
N=107 (%) 
Conditional logistic regression 
(OR, 95% CI); p-value 
Vault hematoma` 28 (2.1) 24 (1.9) 4 (3.7) 1.59; 0.21  4 (3.7) 1.00 (0.20-4.95); 0.27 
Return to the 
operating room 
29 (2.1) 27 (2.2) 2 (1.9) 0.04; 0.84  5 (4.7) 2.50 (0.48-12.9); 0.27 
Postoperative 
transfusion of red 
cells 
25 (1.9) 21 (1.7) 4 (3.7) 2.28; 0.13  4 (3.7) 0.75 (0.17-3.35); 0.71 
Surgical site 
infection (pelvis) 
22 (1.6) 15 (1.2) 7 (6.5) 17.5; <0.001  2 (1.9) 0.29 (0.06-1.37); 0.12 
Readmission within 
30 days  
39 (2.9) 31 (2.5) 8 (7.5) 8.73; 0.003  6 (5.6) 0.75 (0.26-2.16); 0.59 
ICU admission, 
unplanned 
4 (0.3) 4 (0.3) 0 (0.0) 0.34;0.55  1 (0.9) n/a 
 
Blue brackets indicate comparison of SURGIFLO® with all No-SURGIFLO® cases (n=1244). 
Red brackets indicate comparison of SURGIFLO® with age and ASA-matched No-SURGIFLO® cases (n=107). 
 
1 detected clinically and confirmed radiologically
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